kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag, 100µg  

Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag, 100µg

Recombinant Cynomolgus / Rhesus macaque B7-2, Fc Tag (CD6-C5254) is expressed from human 293 cells (HEK293)

Synonym: recombinant, cynomolgus, protein, CD86,B7-2,B70,CD28LG2,LAB72

More details


Availability: within 7 days

312,00 €

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Cynomolgus / Rhesus macaque B7-2, Fc Tag (CD6-C5254) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - His 240 (Accession # G7NXR4).
Predicted N-terminus: Ala 19

Molecular Characterization
Cynomolgus CD86 Fc Chimera is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 52 kDa. The predicted N-terminus is Ala 19. DTT-reduced Protein migrates as 80-110 kDa in SDS-PAGE due to glycosylation.

Less than 1.0 EU per μg of the Cynomolgus CD86 Fc Chimera by the LAL method.

95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CTLA-4, His Tag (Catalog # CT4-C5227) at 2 μg/mL (100 μL/well) can bind Cynomolgus B7-2, Fc Tag (Catalog # CD6-C5254) with a linear range of 0.039-1.25 μg/mL.


(1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
(2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
(3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.